Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|March 17, 2016
Conditions That Make Patients More or Less Likely to Experience Opioid-Induced Constipation
Daniel T. Abazia, PharmD, BCPS, outlines some of the factors that might contribute to a patient's propensity to experience opioid-induced constipation.
Advertisement
Daniel T. Abazia, PharmD, BCPS, outlines some of the factors that might contribute to a patient's propensity to experience opioid-induced constipation.
This video was recorded at Directions in Pharmacy's 6th Annual CE Conference in Plainsboro, NJ.
Advertisement
Related to this article
The data helps pharmaicts predict who will react strongly to mRNA vaccines—giving them a science-backed talking point during respiratory season.
CDC-recommended adult vaccination programs for pneumococcal disease, RSV, influenza, and COVID-19 prevent over 182,000 deaths and generate up to $12 in societal value for every $1 spent.
This article discusses a recent publication examining pharmacy access across Minnesota and explores the complex factors contributing to threatened community health access across the US.
Professional membership and experienced mentor leadership offer new pharmacy technicians a dual advantage, serving as a comprehensive training accelerator.
Artificial intelligence (AI) transforms a chaotic, reactive process into an adaptive, proactive system that improves workflow and patient safety.
New European Respiratory Society (ERS) update makes sotatercept a strong add-on recommendation, opening a fourth pathway for pharmacists to manage.
At the 2026 New England Institute of Ambulatory Care Pharmacists (NEIAP) Annual Forum, Jennifer Goldman detailed how monitoring data drive engagement—and how a new dual sensor readies pharmacists for ketone alerts.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
FDA Approves Rebisufligene Etisparvovec as First Gene Therapy for Children With Sanfilippo Syndrome Type A
3
Radioligand Therapy Doesn’t Need to Be Risk-Free—It Needs to Be Worth It
4
FDA Reduces Monitoring Time for First Two Tarlatamab Doses
5